Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922269 | 0.84 | CYP3A4 (0.76) | CYP3A4CYP1A2ALDH1A1MAPTCYP2C9 | |
| SCHEMBL6364807 | 0.81 | CYP1A2 (0.46) | CYP3A4CYP1A2ALDH1A1MAPTCYP2C9 | |
| SCHEMBL2808492 | 0.79 | CYP3A4 (0.54) | CYP3A4CYP1A2ALDH1A1MAPTCYP2C9 | |
| SCHEMBL27265322 | 0.78 | MMP2 (0.39) | CYP3A4CYP1A2ALDH1A1MAPTCYP2C9 | |
| SCHEMBL14269645 | 0.77 | CYP3A4 (0.60) | CYP3A4CYP1A2ALDH1A1MAPTCYP2C9 | |
| SCHEMBL28392107 | 0.77 | CYP3A4 (0.60) | CYP3A4CYP1A2ALDH1A1MAPTCYP2C9 | |
| SCHEMBL11651688 | 0.76 | CYP3A4 (0.59) | CYP3A4CYP1A2ALDH1A1MAPTCYP2C9 | |
| SCHEMBL3978730 | 0.75 | CYP3A4 (0.55) | CYP3A4CYP1A2ALDH1A1MAPTCYP2C9 | |
| SCHEMBL336717 | 0.75 | CYP3A4 (0.52) | CYP3A4CYP1A2ALDH1A1MAPTCYP2C9 | |
| SCHEMBL1258715 | 0.75 | CYP3A4 (0.52) | CYP3A4CYP1A2ALDH1A1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028568-B | Synthesis method of 3-selenoindole compound promoted by visible light | 南通大学 | 2023-12-19 | — | — | CN | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| CN-116283799-A | Quinazoline methionine adenosyltransferase 2A inhibitors | 南京正大天晴制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | YUMANITY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| CN-115028568-A | Synthesis method of visible light promoted 3-selenoindole compound | 南通大学 | 2022-09-09 | — | — | CN | disclosed |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-113573708-A | Polyvalent derivatives of emoxidine | 阿尔萨泰克公司 | 2021-10-29 | — | — | CN | disclosed |
| US-10597493-B2 | Polyimide precursor composition and method of preparing polyimide molded article | FUJI XEROX CO., LTD. (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20180215873-A1 | POLYIMIDE PRECURSOR COMPOSITION AND METHOD OF PREPARING POLYIMIDE MOLDED ARTICLE | FUJI XEROX CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-20180118769-A1 | PHOSPHORUS-CONTAINING HETEROCYCLES AND A METHOD FOR MAKING AND USING | UNIVERSITY OF OREGON (US) | 2018-05-03 | — | — | US | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-6664408-B2 | Contacting a polyoxometalate and an amine in the presence of a diimide | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2003-12-16 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020165405-A1 | Process for preparing organically-substituted polyoxometalates | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2002-11-07 | — | — | US | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CYP3A4 4374/4885CYP1A2 4367/4885ALDH1A1 1538/4885 |
| US-20020165405-A1 | Process for preparing organically-substituted polyoxometalates | TET2, ALKBH3, FTO | CYP3A4 449/4885CYP1A2 1017/4885ALDH1A1 1029/4885 |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | CYP3A4 4082/4885CYP1A2 4052/4885ALDH1A1 3439/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | CYP3A4 373/4885CYP1A2 166/4885ALDH1A1 389/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | CYP3A4 207/4885CYP1A2 85/4885ALDH1A1 261/4885 |
| US-20180118769-A1 | PHOSPHORUS-CONTAINING HETEROCYCLES AND A METHOD FOR MAKING AND USING | INPPL1, ALPL, PAICS | CYP3A4 1307/4885CYP1A2 2514/4885ALDH1A1 2661/4885 |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | CYP3A4 373/4885CYP1A2 166/4885ALDH1A1 389/4885 |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | CYP3A4 2972/4885CYP1A2 2811/4885ALDH1A1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.